Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

High-dose melphalan 140 mg/m(2) is the standard of care for patients with multiple myeloma (MM) with renal insufficiency (RI). Palifermin as a cytoprotective agent has demonstrated efficacy in reducing the intensity and duration of oral mucositis (OM) in patients who receive intensive chemotherapy/r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Abidi, Muneer H., Agarwal, Rishi, Ayash, Lois, Deol, Abhinav, Al-Kadhimi, Zaid, Abrams, Judith, Cronin, Simon, Ventimiglia, Marie, Lum, Lawrence, Zonder, Jeffrey, Ratanatharathorn, Voravit, Uberti, Joseph
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782285/
https://ncbi.nlm.nih.gov/pubmed/22453252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2012.03.010
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak